Teresa Patterson, MD
Family Medicine · Tullahoma, TNNPI 1265494488
Payments from drug & device makers
Across 345 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Mannkind Corporation$973
- Otsuka America Pharmaceutical, Inc.$740
- Novo Nordisk$698
- Amgen$556
- Medline Industries LP$275
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,71397%
- Education$2093%
- Gifts$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,293 |
| Mannkind Corporation | 78 | $973 |
| Otsuka America Pharmaceutical, Inc. | 43 | $740 |
| Novo Nordisk | 23 | $698 |
| Amgen | 34 | $556 |
| Medline Industries LP | 2 | $275 |
| Akebia Therapeutics Inc | 12 | $253 |
| Bayer | 10 | $239 |
| Lilly USA, LLC | 14 | $220 |
| Novartis | 11 | $211 |
| GSK | 10 | $187 |
| AbbVie | 4 | $175 |
| Amarin Pharma, Inc. | 10 | $149 |
| Merck | 8 | $137 |
| Boehringer Ingelheim | 6 | $120 |
| OPKO Pharmaceuticals, LLC | 7 | $114 |
| Vifor Pharma, Inc. | 6 | $83 |
| Esperion Therapeutics, Inc. | 5 | $74 |
| Avion Pharmaceuticals | 2 | $53 |
| Calliditas Therapeutics US Inc. | 2 | $52 |
| Phadia US Inc. | 3 | $45 |
| Aurinia Pharma U.S., Inc. | 2 | $39 |
| Mallinckrodt Enterprises LLC | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Boston Scientific | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Rockwell Medical, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
| Ascend Therapeutics US, LLC | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,934 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 108 | $123,606 |
| XphozahTenapanor Hcl | 23 | $103,369 |
| JardianceEmpagliflozin | 75 | $72,131 |
| FarxigaDapagliflozin Propanediol | 69 | $57,463 |
| TrulicityDulaglutide | 37 | $43,214 |
| OzempicSemaglutide | 24 | $32,771 |
| EliquisApixaban | 27 | $31,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $27,974 |
| ProsolParenteral Amino Acid 20% No.1 | 108 | $22,509 |
| JanuviaSitagliptin Phosphate | 13 | $13,602 |
| KerendiaFinerenone | 16 | $11,271 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $8,350 |
| XareltoRivaroxaban | 14 | $7,483 |
| Ezetimibe | 215 | $4,108 |
| Fenofibrate | 202 | $2,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $220 | $166,821145 claims |
| Boehringer IngelheimJardiance | $120 | $72,13175 claims |
| AstraZenecaFarxiga | $1,293 | $57,46369 claims |
| Novo NordiskOzempic | $698 | $32,77124 claims |
| PfizerEliquis | $19 | $31,62827 claims |
| GSKTrelegy Ellipta | $187 | $27,97421 claims |
| MerckJanuvia | $137 | $13,60213 claims |
| BayerKerendia | $239 | $11,27116 claims |
| AbbVieSynthroid | $175 | $1,77518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Tullahoma
- Marcus LeeTullahoma$1.5M
- John AndersonTullahoma$23K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.